ANTIBACTERIAL THERAPY OF PLAGUE (literature review)

Authors

  • Tatiana V MEKA-MECHENKO M Aikimbayev National Scientific Center for Especially Dangerous Infections of the Ministry of Healthcare of the Republic of Kazakhstan
  • Ziyat Zh ABDEL M Aikimbayev National Scientific Center for Especially Dangerous Infections of the Ministry of Healthcare of the Republic of Kazakhstan
  • Elmira Zh BEGIMBAYEVA M Aikimbayev National Scientific Center for Especially Dangerous Infections of the Ministry of Healthcare of the Republic of Kazakhstan
  • Galina G KOVALEVA M Aikimbayev National Scientific Center for Especially Dangerous Infections of the Ministry of Healthcare of the Republic of Kazakhstan
  • Larissa Y LUKHNOVA M Aikimbayev National Scientific Center for Especially Dangerous Infections of the Ministry of Healthcare of the Republic of Kazakhstan
  • Uinkul A IZBANOVA M Aikimbayev National Scientific Center for Especially Dangerous Infections of the Ministry of Healthcare of the Republic of Kazakhstan
  • Zhandos S DALIBAYEV M Aikimbayev National Scientific Center for Especially Dangerous Infections of the Ministry of Healthcare of the Republic of Kazakhstan

DOI:

https://doi.org/10.31082/1728-452X-2021-225-3-36-42

Keywords:

plague, antibacterial drugs and therapy, sensitivity, resistance, strains, Y. pestis

Abstract

Population growth and its high migration activity cause a risk of the global spread of especially dangerous infectious diseases, including plague. Sensitivity to antibacterial drugs is an important feature of Yersinia pestis strains isolated in natural plague foci. The reported antibiotic resistance of plague pathogen decreases the effectiveness of specific antibiotic therapy for this infection. This paper reviews literary data on the antibacterial therapy of plague.
The purpose of the study was to analyze literary sources on antibacterial therapy of plague and describe the current state of the problem.
Material and methods. Literary review and source analysis covered the Scopus, Thomson Reuter, Google Scholar, e.library.ru, and PubMed databases. The search depth was 30 years
(1988-2018). Out of 200 sources revealed, 39 (26 in English and 13 in Russian) were selected for further analysis.
Keywords used for inclusion in the study were: plague, antibacterial drugs and therapy, sensitivity, resistance, strains and Y. pestis.
Results and discussion. The data on the promptness and adequacy of antibiotic administration was reviewed. Such antibiotics as streptomycin, gentamicin, tetracycline or doxycycline, and chloramphenicol are commonly used in the clinic and recommended by the WHO. Fluoroquinolones, such as ciprofloxacin, were also efficient in animal and in vitro studies. Streptomycin has been the most effective and available clinical therapy. Gentamicin was an acceptable and preferred alternative to streptomycin in the United States and several other countries. Recently, several studies have suggested a drug combination that may be more effective – streptomycin or gentamicin combined with tetracycline or doxycycline.
Conclusions. Aminoglycosides are the leading group of drugs effective against plague infection. Streptomycin remains the reference drug used to compare the effectiveness of other antibiotics.

References

Wong J.D., Barash J.R., Sandfort R.F., Janda J.M. Susceptibilities of Yersinia pestis strains to 12 antimicrobial agents // Antimicrob. Agents Chemother. 2000;44(7):1995-1996. doi: 10.1128/AAC.44.7.1995-1996.2000

Атшабар Б.Б., Айкимбаев A.M., Аубакиров С.А. и др. Эпизоотологические и социальные предпосылки заболеваний чумой людей в 1999 г. в Казахстане и их клинико-эпидемиологические характеристики // Проблемы особо опасных инфекций. 2000;80:14-21

Lyamuya E.F., Nyanda P., Mohammedali H., Mhalu F. Laboratory studies on Yersinia pestis during the 1991 outbreak of plague in Lushoto, Tansania // J. Trop. Med. Hyg. 1992;95(5):335-338

Cabanel N., Bouchier C., Rajerison M., Carniel E. Plasmid-mediated doxycycline resistance in a Yersinia pestis strain isolated from a rat // International Journal of Antimicrobial Agents. 2018;51:249–254

Онищенко Г.Г., Фёдоров Ю.М., Алексев В.В. и др. Задачи противодействия биологическим угрозам на современном этапе / Mатериалы IX съезда ВНПОЭМП. М., 2007. Т.З. С. 129-130

Воробьев А.А. Оценка вероятности использования биоагентов в качестве биологического оружия // Эпидемиол. и инф. болезни. 2001;6:54-56

Inglesby T.V., Dennis D.T., Henderson D.A., et al. Plague as a biological weapon: medical and public health management // External Working Group on Civilian Biodefense // JAMA. 2000;283(17):2281-2290. PMID: 10807389. doi: 10.1001/jama.283.17.2281

Koirala J. Plague: disease, management, and recognition of act of terrorism // External Infect Dis Clin North Am. 2006;20(2):273-287. PMID: 16762739. doi: 10.1016/j.idc.2006.02.004

Boulanger L.L., Ettestad P., Fogarty J.D., Dennis D.T., Romig D., Mertz G. Gentamicin and tetracyclines for the treatment of human plague: Review of 75 cases in New Mexico, 1985–1999 // External Clin Infect Dis. 2004;38(5): 663-669. PMID: 14986250. doi: 10.1086/381545

Mwengee W., Butler T., Mgema S., Mhina G., Almasi Y., Bradley C., Formanik J.B., Rochester C.G. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. // External Clin Infect Dis. 2006;42(5):614-621. PMID: 16447105. doi: 10.1086/500137

Goldmann D.A. Contemporary challenges for hospital epidemiology // Am J Med. 1991;91(3B):8S-15S. doi: 10.1016/0002-9343(91)90337-w

Gourgouli K., Mouroutsou M., Varjioti E., Kondii L., Chronopoulos G., Baliaga S. et al. Comparison of bacterial resistance before and after restriction policy in the use of antibiotics // Proceedings of the 7th ESCMID. 1995. 57 p.

Courvalin P. Impact of molecular biology on antibiotic susceptibility: testing and therapy // Am J Med. 1995;99(6A):21S-25S. doi: 10.1016/s0002-9343(99)80281-2

Marr J.J., Moffet H.L., Kunin C.M. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the infectious diseases society of America // J Infect Desease. 1988;157(5):869-876. doi: 10.1093/infdis/157.5.869

Решедько Г.К. Механизмы резистентности к аминогликозидам у нозокомиальных грамотрицательных бактерий в России: результаты многоцентрового исследования // Клиническая микробиология и антимикробная химиотерапия. 2001;2(3):111-126

Yun-fang Li, De-biao Li, Hong-sheng Shao, Hong-jun Li, Yue-dong Han Plague in China 2014-All sporadic case report of pneumonic plague // BMC Infect Dis. 2016;16:85. doi: 10.1186/s12879-016-1403-8

Smego RA, Frean J, Koornhof HJ. Yersiniosis I: microbiological and clinicoepidemiological aspects of plague and non-plague Yersinia infections // Eur J Clin Microbiol Infect Dis. 1999;18(1):1-15. doi: 10.1007/s100960050219

Perry RD, Fetherston JD. Yersinia pestis: etiologic agent of plague // Clin Microbiol Rev. 1997;10(1):35-66. doi: 10.1128/CMR.10.1.35

Dawa W, Pan WJ, Gu XY, Zhang SQ, Dawa C, Yi X, et al. Clinical features, diagnosis and treatment of 5 cases of primary pneumonic plague in Tibet in 2010 // Chin J Tuberc Respir Dis. 2011;34(6):404-408

Chinese CDC. Plague diagnosis scheme (on trial). Available from: http://www.chinacdc.cn/jkzt/crb/sy/jszl_2217/201111/t20111117_54777.htm. November 2011

Арутюнов Ю.И., Пичурина Н.Л., Судьина Л.В., Трухачев А.Л. Чума в Китае: эпидемиологические и эпизоотологические аспекты // Инфекционные болезни: новости, мнения, обучение. 2019;8(3):70–77

Mwengee W., Butler T., Mgema S., Mhina G., Almasi Y., Bradley C. et al. Treatment of plague with gentalmicin or doxycycline in a randomized clinical trial in Tanzania // Clin Infect Dis. 2006;42(5):614-621. doi: 10.1086/500137

Boulanger L.L., Ettestad P., Fogarty J.D., Dennis D.T., Romig D., Mertz G. Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985–1999 // Clin Infect Dis. 2004;38(5):663-669. doi: 10.1086/381545

Lemaître N., Ricard I., Pradel E., Foligné B., Courcol R., Simonet M. et al. Efficacy of ciprofloxacin-gentamicin combination therapy in murine bubonic plague // PLoS ONE. 2012;7(12):e52503. doi: 10.1371/journal.pone.0052503

Rosenzweig J.A., Brackman S.M., Kirtley M.L., Sha J., Erova T.E., Yeager L.A. et al. Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin // Antimicrob Agents Chemother. 2011;55(11):5034-5042. doi: 10.1128/AAC.00632-11

Galimand M., Carniel E., Courvalin P. Resistance of Yersinia pestis to antimicrobial agents // Antimicrob Agents Chemother. 2006;50(10):3233-3236. doi: 10.1128/AAC.00306-06

Anisimov A.P., Amoako K.K. Treatment of plague: promising alternatives to antibiotics // J Med Microbiol. 2006;55(11):1461-1475. doi: 10.1099/jmm.0.46697-0

Kiersten J. Kugeler, J. Erin Staples, Alison F. Hinckley, Kenneth L. Gage, and Paul S. Mead Epidemiology of Human Plague in the United States, 1900–2012 // Emerg Infect Dis. 2015;21(1):16-22. doi: 10.3201/eid2101.140564

World Health Organization. WHO recommended surveillance standards. 2nd ed. Geneva: The Organization; 1999. P. 95–96 [cited 2017 Nov 22]. http://www.who.int/csr/resources/publications/surveillance/whocdscsrisr992.pdf.

Benenson AS (ed): Plague. In: Control of Communicable Diseases Manual // American Public Health Association. Washington, DC. 1995. P. 353-358

Антонов В. А., Жукова С. И., Демьянова О. Б., Абдрахманова Р. О. Проблема экстренной профилактики инфекционных заболеваний // Волгоградский научно-медицинский журнал. 2015;1:24-31

Падейская Е. Н. Фторхиноллоны в клинике инфекционных заболеваний // Инфекции и антимикробная терапия. 2005:11(3):107-144

Рыжко И.В., Щербанюк А.И., Смородинова Ю.В. и др. Чрезвычайные ситуации междунар. Значения в общест. здравоохранении в решениях Санкт-Петербургского саммита «группы восьми» и санит. охрана территорий государств-участников СНГ: Mатер. VII межгосударственной науч.-практич. конф. государств-участников СНГ. Оболенск, 2006. С. 237-238

Щипелева И. А., Марковская Е. И. Антибактериальная терапия чумы. Исторический срез и взгляд в будущее // Антибиотики и химиотерапия. 2016;61(9-10):74-80

Byrne W.R., Welkos S.L., Pitt M.L. et al. Antibiotic treatment of experimental pneumonic plague in mice // Antimicrob Agents Chemother. 1998;42(3):675-681. doi: 10.1128/AAC.42.3.675

Молдаван И.А. Экспериментальное обоснование преимуществ сочетанной специфической и экстренной профилактики чумы: aвтореф. дис. … канд. биол. наук. Ростов-на-Дону, 2005. 22 с.

Рыжко И.В., Мишанькин М.Б., Тынянова В.И., Цураева Р.И., Молдаван И.А. и др. Инфекционно-токсическая модель чумной инфекции у белых мышей: перспективы использования для оценки эффективности вакцинных и антибактериальных препаратов // Научная мысль Кавказа. 2006;12:321-329

Тришина А.В., Веркина Л.М., Щипелева И.А. Егиазарян Л.А. Эффективность нетилмицина на модели экспериментальной инфекционно-токсической чумы белых мышей: Матер. III Санкт-Петербург. международ. эколог. форума. 2014 (спец. выпуск). 115 c.

Егиазорян Л.А., Тришина А.В., Веркина Л.М., Щипелева И.А. Ципрофлоксацин и моксифлоксацин в лечении экспериментальной инфекционно-токсической чумы белых мышей, вызванной FI+ FI-вариантами возбудителя // Актуал. пробл. эпидемиол. и профилакт. мед: Матер. VI Всерос. науч.-практ. конф. молодых учён. и спец-в Роспотребнадзора. Ставрополь. 2014. С. 81-82

Published

2021-12-15

Issue

Section

Articles

Most read articles by the same author(s)